The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
On Sunday 16 June at the 24th Congress of the European Hematology Association (EHA), Shaji Kumar, Mayo Clinic, Rochester, MN, US, presented the results of the phase III BELLINI trial (NCT02755597), which investigated the efficacy and safety of venetoclax in patients with relapsed or refractory multiple myeloma (RRMM).1
Venetoclax (Ven) is a first-in-class, selective inhibitor of the anti-apoptotic protein BCL2, and thus can induce myeloma cell death. It has shown promising clinical activity and manageable safety both alone,2 and in combination with bortezomib (B) and dexamethasone3 (d) in phase I studies for RRMM.
This multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of venetoclax addition to bortezomib and dexamethasone (VenBd) in patients with RRMM. Patients were randomized to Bd or VenBd, with progression-free survival (PFS) by independent review committee (IRC) as the primary endpoint. Secondary endpoints included, overall response rate (ORR), overall survival (OS), ≥ very good partial response (VGPR), and quality of life (QoL) based on patient reported outcomes (PRO).
|
VenBd (n=194) |
Placebo+Bd (n=97) |
---|---|---|
Median age (range) ≥65 years old |
66 (36–87) 56% |
65 (44–83) 54% |
MM International Staging System (ISS): Stage 1 Stage 2 Stage 3 |
42% 36% 20% |
50% 33% 14% |
Number of prior lines: 1 2–3 |
47% 53% |
45% 55% |
Cytogenetics: High-risk [t(4;14) or t(14;16) or del(17p)] Standard risk Unknown |
17% 78% 5% |
19% 77% 4% |
t(11;14) status: Positive Negative Unknown |
11% 84% 5% |
16% 79% 5% |
BCL2 expression (immunohistochemistry): High Low |
78% 22% |
81% 19% |
ISS, international staging system; VenBd, venetoclax, bortezomib and dexamethasone |
|
VenBd (n=194) |
Placebo+Bd (n=97) |
p value |
---|---|---|---|
ORR |
82% |
68% |
0.008 |
≥CR |
26% |
5% |
<0.001 |
≥VGPR |
59% |
36% |
<0.001 |
MRD<10-4 |
19% |
3% |
<0.001 |
MRD<10-5 |
13% |
1% |
<0.001 |
MRd<10-6 |
7% |
1% |
0.026 |
CR, complete response; MRD, minimum residual disease; ORR, overall response rate; VGPR, very good partial response; VenBd, venetoclax, bortezomib and dexamethasone |
PD, progressive disease; VenBd, venetoclax, bortezomib and dexamethasone | ||
Safety population |
VenBd (n=193) |
Placebo+Bd (n=96) |
---|---|---|
All deaths Infection PD Other |
21% 7% 9% 5% |
11% 2% 8% 1% |
Deaths occurring within 30 days of last dose: Infection PD Other |
7% 4% 1% 2% |
1% 0 1% 0 |
Deaths occurring after 30 days of last dose: Infection PD Other |
14% 3% 8% 3% |
10% 2% 7% 1% |
The investigators of the trial performed a PFS subgroup analysis to identify potential patient populations that benefit the most from venetoclax treatment without the serious infection adverse events identified in the total cohort
Prof. Shaji Kumar provided a summary of the safety signals that were associated with venetoclax in this trial:
‘We observed increased numbers of deaths in the venetoclax arm, even though the rates of the adverse events, including those for serious adverse events were similar between the groups. The increased deaths were primarily related to infections, especially in the setting of disease progression. No specific organisms have been identified, though bacterial was most common. When subgroups were examined, the increased risk of death seemed to be particularly evident in patients without t(11;14), those with high-risk cytogenetics, and in those with low expression of BCL-2. In contrast, patients with t(11;14) had a significant improvement in progression-free survival without any deleterious impact. The immediate future focus will be to better define the role of the drug in this subgroup, along with development of any applicable biomarkers. Subsequently, various combinations will be explored in the other subgroups.’
References